| Patents for C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836) |
|---|
| 09/21/2004 | US6794496 Immunoassay for LSD and 2-oxo-3-hydroxy-LSD |
| 07/21/2004 | CN1514843A Somatostatin-dopamine chimeric analogs |
| 05/27/2004 | US20040101550 Transdermal therapeutic system |
| 05/13/2004 | US20040092744 Process for preparing crystalline form I of cabergoline |
| 05/13/2004 | US20040092544 Synergistic mixture containing dopamine agent; muscular disorders; analgesics |
| 04/27/2004 | US6727363 From toluene/diethyl ether mixture; recovering, drying |
| 04/15/2004 | US20040072855 Crystallization, mixing with solvent at low temperature; therapy for central nervous system disorders |
| 03/31/2004 | EP1401863A1 Somatostatin-dopamine chimeric analogs |
| 02/24/2004 | US6696568 Process and intermediates for production of cabergoline and related compounds |
| 02/12/2004 | US20040028723 Matrix with permeable reservoir containing ergoline compound; diffusion barrier |
| 02/10/2004 | US6689384 Stable pergolide mesylate and process for making same |
| 01/29/2004 | WO2003076439A3 1-allyl ergot alkaloid derivatives, method for producing the same and the use thereof for preventing and treating migraine |
| 01/20/2004 | US6680327 Crystalline form VII of cabergoline |
| 01/15/2004 | WO2003078432A3 Process for the synthesis of pergolide |
| 01/14/2004 | EP1379526A1 Process and intermediates for production of cabergoline and related compounds |
| 01/06/2004 | US6673806 Crystalline form II cabergoline |
| 12/18/2003 | US20030232871 Crystalline parecoxib sodium |
| 12/11/2003 | WO2003078392A3 Process for preparing crystalline form i of cabergoline |
| 10/22/2003 | CN1450065A Haptens, immunogens, and conjugates for 2-oxo-3-hydroxy LSD |
| 10/16/2003 | US20030194748 Method for labeling with tritium |
| 10/02/2003 | US20030187013 Central nervous system disorders |
| 09/30/2003 | CA2095593C One-pot process |
| 09/25/2003 | WO2003078433A1 Process for preparing crystalline form i of cabergoline |
| 09/25/2003 | WO2003078432A2 Process for the synthesis of pergolide |
| 09/25/2003 | WO2003078408A1 Crystalline parecoxib sodium |
| 09/25/2003 | WO2003078392A2 Process for preparing crystalline form i of cabergoline |
| 09/25/2003 | CA2479140A1 Process for preparing crystalline form i of cabergoline |
| 09/25/2003 | CA2478500A1 Crystalline parecoxib sodium |
| 09/25/2003 | CA2478149A1 Process for preparing crystalline form i of cabergoline |
| 09/24/2003 | EP1272489B1 Process for preparing crystalline form i of cabergoline |
| 09/23/2003 | CA2106371C Process for the preparation of ergoline derivatives |
| 09/18/2003 | WO2003076439A2 1-allyl ergot alkaloid derivatives, method for producing the same and the use thereof for preventing and treating migraine |
| 08/20/2003 | EP1133297B1 Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline |
| 08/13/2003 | EP1133296B1 Novel therapeutic application of nicergoline |
| 08/07/2003 | US20030149067 Crystallisation of the desired crystalline form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals |
| 07/31/2003 | US20030144516 Crystalline form VII of cabergoline |
| 07/31/2003 | US20030143655 For competitive immunoassays for detection of lysergic acid (LAD) metabolite; drug screening; forensics |
| 07/17/2003 | US20030134869 Novel therapeutic use of nicergoline |
| 06/25/2003 | EP1321466A1 Haptens, immunogens, antibodies and conjugates for 2-oxo-3-hydroxy LSD |
| 06/18/2003 | EP1318813A1 Stable pergolide mesylate and process for making same |
| 05/21/2003 | EP1311249A1 Transdermal therapeutic system |
| 05/21/2003 | EP1311248A1 Transdermal therapeutic system for treating restless-legs-syndrome |
| 05/21/2003 | CN1419554A Process for preparing crystalline form 1 of cabergoline |
| 05/14/2003 | CN1418213A Crgstalline form II of cabergoline |
| 04/23/2003 | EP1303278A1 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 04/15/2003 | US6548645 Immunoassay for 2-oxo-3-hydroxy LSD |
| 02/26/2003 | EP1285902A1 Method for labeling with tritium |
| 02/05/2003 | EP1280803A1 Crystalline form ii of cabergoline |
| 01/16/2003 | US20030013131 Immunoassay for LSD and 2-oxo-3-hydroxy-LSD |
| 01/08/2003 | EP1272489A1 Process for preparing crystalline form i of cabergoline |
| 01/08/2003 | EP1196415B1 Method for preparing lysergic acid |
| 12/19/2002 | WO2002100888A1 Somatostatin-dopamine chimeric analogs |
| 12/19/2002 | US20020192703 Composition for use in the detection of lysergic acid diethylamide in sample |
| 12/18/2002 | EP1265894A1 Crystalline form vii of cabergoline |
| 11/28/2002 | US20020177709 Parkinson's disease |
| 11/05/2002 | US6476199 Reagents for lysergic acid diethylamide immunoassay |
| 10/31/2002 | WO2002085902A1 Process and intermediates for production of cabergoline and related compounds |
| 10/31/2002 | CA2412861A1 Process and intermediates for production of cabergoline and related compounds |
| 10/22/2002 | US6469019 Prevention/treatment of motor neuron diseases; amyotrophic lateral sclerosis |
| 09/17/2002 | US6451818 Therapeutic use of 1,6-dimethyl-8β-hydroxymethyl-10α-methoxyergoline |
| 05/30/2002 | US20020065294 Novel therapeutic use of 1,6-dimethyl-8b-hydroxymethyl-10a-methoxyergoline |
| 05/28/2002 | US6395901 Multistage reaction with calcium borohydride, alkylsulfonyl chloride, alkali metal mercapto compound and reducing agent for preparation of compounds active in the treatment of parkinson's disease, |
| 05/23/2002 | WO2002034267A8 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 05/14/2002 | US6388079 Reacting 9,10-dihydrolyserol with acid anhydride while heating; reduction |
| 05/09/2002 | US20020054904 Stable pergolide mesylate and process for making same |
| 05/02/2002 | WO2002034267A1 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 05/02/2002 | DE10053397A1 Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen Use of a dopaminergic agent for the treatment of dopaminergic treatable diseases |
| 04/17/2002 | EP1196415A1 Method for preparing lysergic acid |
| 03/28/2002 | DE10043321A1 Transdermales therapeutisches System Transdermal therapeutic system |
| 03/19/2002 | US6358967 Ergoline amine derivatives with blood pressure lowering effect |
| 02/28/2002 | WO2002015890A1 Transdermal therapeutic system |
| 02/28/2002 | WO2002015889A1 Transdermal therapeutic system for treating restless-legs-syndrome |
| 02/27/2002 | CN1337960A Piperdine and piperazine derivatives as inhibitors of the ABETA fibril formation |
| 02/14/2002 | WO2002011727A1 Stable pergolide mesylate and process for making same |
| 02/14/2002 | CA2418915A1 Stable pergolide mesylate and process for making same |
| 01/15/2002 | US6339095 Therapeutic use of 1, 6-dimethyl-8β-hydroxymethyl-10-α-methoxyergoline |
| 01/03/2002 | US20020002170 Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation |
| 12/06/2001 | WO2001092188A1 Method for labeling with tritium |
| 11/29/2001 | US20010047011 Preventing and treating motor neuron diseases such as ALS |
| 11/22/2001 | US20010044448 Prevention/treatment of motor neuron diseases; amyotrophic lateral sclerosis |
| 11/22/2001 | US20010044118 Immunoassay for LSD and 2-oxo-3-hydroxy-LSD |
| 11/07/2001 | EP1150971A1 Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation |
| 10/24/2001 | EP1148339A2 Immunoassay for LSD and 2-Oxo-3-Hydroxy-LSD |
| 10/24/2001 | EP1147106A1 Process for the preparation of alkyl mercapto methyl ergoline derivatives |
| 10/10/2001 | EP1141011A2 Compounds and methods to inhibit or augment an inflammatory response |
| 10/07/2001 | CA2342961A1 Immunoassay for lsd and 2-oxo-3-hydroxy-lsd |
| 10/04/2001 | WO2001072747A1 Crystalline form ii of cabergoline |
| 10/04/2001 | WO2001072746A1 Crystalline form vii of cabergoline |
| 10/04/2001 | CA2403557A1 Crystalline form vii of cabergoline |
| 10/04/2001 | CA2399540A1 Crystalline form ii of cabergoline |
| 09/27/2001 | WO2001070740A1 Process for preparing crystalline form i of cabergoline |
| 09/27/2001 | CA2402836A1 Process for preparing crystalline form i of cabergoline |
| 09/19/2001 | EP1133297A1 Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline |
| 09/19/2001 | EP1133296A1 Novel therapeutic application of nicergoline |
| 08/16/2001 | EP0628042B1 Serotoninergic ergoline derivatives |
| 07/04/2001 | EP1112271A1 Ergoline amine derivatives with blood pressure lowering effect |
| 06/05/2001 | US6242603 Process of preparing lysergic acid |
| 05/31/2001 | WO2000042071A3 Compounds and methods to inhibit or augment an inflammatory response |
| 05/30/2001 | EP0885222B1 Heterocyclyl-ergoline derivatives as 5-ht1a receptor ligands |
| 04/24/2001 | US6221870 Treatment of depression, anxiety, bipolar disorders and adhd |